Alnylam Pharmaceuticals Inc (ALNY)vsCue Biopharma (CUE)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
CUE
Cue Biopharma
$0.25
-4.24%
HEALTHCARE · Cap: $25.96M
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 13422% more annual revenue ($3.71B vs $27.47M). ALNY leads profitability with a 8.5% profit margin vs -96.9%. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ALNY
Hold49
out of 100
Grade: D+
CUE
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Intrinsic value data unavailable for CUE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -121.1% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : CUE
The strongest argument for CUE centers on Price/Book. Revenue growth of 12.9% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : CUE
The primary concerns for CUE are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while CUE is a turnaround play — different risk/reward profiles.
CUE carries more volatility with a beta of 1.55 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (49/100 vs 44/100) and 84.9% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Cue Biopharma
HEALTHCARE · BIOTECHNOLOGY · USA
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biological drugs for the selective modulation of the human immune system to treat a variety of cancers, chronic infectious diseases, and autoimmune disorders. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?